ArticleActa oncologica (Stockholm, Sweden)2025

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

Alaa Kheir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.